• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Helix BioPharma Gives Update on L-DOS47 Phase II Study

    Bryan Mc Govern
    May. 01, 2019 07:45AM PST
    Biotech Investing

    Helix BioPharma announced the Trial Steering Committee reviewed safety data from the first dosing cohort of the Company’s LDOS003 study.

    Helix BioPharma (TSX:HBP) announced the Trial Steering Committee (TSC) reviewed safety data from the first dosing cohort of the Company’s LDOS003 study.

    As quoted in the press release:

    No serious adverse events or dose limiting toxicities were observed. TSC recommended that Helix begin enrollment of patients into the second dosing cohort.

    LDOS003 is a Phase II, open-label, randomized study of immunoconjugate L-DOS47 in combination with vinorelbine and cisplatin as compared to vinorelbine and cisplatin alone in patients with lung adenocarcinoma.

    “We are very encouraged that the first dosing cohort of this L-DOS47 phase II study in combination with chemotherapy has been completed,” said Heman Chao, Helix’s Chief Executive Officer.  “We look forward to receiving more data as we advance the L-DOS47 development program.”

    Click here to read the full press release.

    helix biopharmatsx:hbp
    The Conversation (0)

    Go Deeper

    AI Powered
    FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

    FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone

    Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES